Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:7664 |
Name | endometrial mixed adenocarcinoma |
Definition | An endometrial adenocarcinoma that is composed of both type I (endometrioid) and type II (serous or clear cell type) tumors, with at least 10% of each component. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer uterine cancer endometrial cancer endometrial carcinoma endometrial adenocarcinoma endometrial mixed adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA N345K | Copanlisib | endometrial mixed adenocarcinoma | no benefit | detail... |
PIK3CA H1047X | Copanlisib | endometrial mixed adenocarcinoma | no benefit | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03914612 | Phase III | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | Active, not recruiting | USA | CAN | 3 |
NCT04196257 | Phase I | BP1001-A BP1001-A + Paclitaxel | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | Unknown status | USA | 0 |
NCT04197219 | Phase II | Axitinib + Pembrolizumab | Pembrolizumab With Axitinib in Recurrent Endometrial Cancer | Withdrawn | 0 | |
NCT04750941 | Phase II | Copanlisib | Study of Copanlisib and Ketogenic Diet | Active, not recruiting | USA | 0 |
NCT05542407 | Phase I | Atezolizumab + ONC201 | ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | Recruiting | USA | 0 |
NCT05603910 | Phase I | Lenvatinib + Pembrolizumab | Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma | Recruiting | USA | 0 |
NCT05826015 | Phase I | AVB-S6-500 AVB-S6-500 + Paclitaxel | AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer | Withdrawn | 0 |